rosiglitazone has been researched along with gossypol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Gao, M; He, F; He, J; Huang, Y; Li, B; Li, X; Lian, J; Shi, C; Zeng, Y | 1 |
2 other study(ies) available for rosiglitazone and gossypol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
The PPARĪ³ agonist rosiglitazone sensitizes the BH3 mimetic (-)-gossypol to induce apoptosis in cancer cells with high level of Bcl-2.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gossypol; Humans; Male; MAP Kinase Kinase 4; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-bcl-2; Rosiglitazone | 2018 |